Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 24;10:5621–5631. doi: 10.2147/OTT.S150701

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 He et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Effects of GLP-1R agonists on PI3K/Akt and MAPK/Erk signaling pathways in PTC cell lines.

Notes: PTC cells were treated with liraglutide or exenatide (100 nmol/L) for 48 h. (A) IHH4, (B) BCPAP, and (C) TPC-1.

Abbreviations: Akt, AKT serine/threonine kinase; BCPAP, normal human thyroid cells; Erk, extracellular signal-regulated kinase; GLP-1R, glucagon-like peptide-1 receptor; IHH4, human papillary thyroid carcinoma cell line; MAPK, mitogen-activated protein kinase; PI3K, phosphoinositol-3 kinase; PTC, papillary thyroid cancer; TPC-1, human thyroid cancer cell line.